01 / IDENTITY

Compound Profile

16

AMINO ACIDS

~1.82

kDa MW

SC

ROUTE

~30m

HALF-LIFE

SEQUENCE

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

ORIGIN

Isolated C-terminal fragment of human GH (residues 176–191). Contains the fat-mobilizing domain with disulfide bridge intact. Developed by Metabolic Pharmaceuticals (Australia).

MECHANISM

Binds β3-adrenergic receptors in adipose tissue. Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) — without engaging IGF-1 axis or GH receptor pathways.

PRIMARY EFFECT

Targeted lipolysis — preferentially mobilizes visceral and subcutaneous adipose fat. Does NOT affect glucose metabolism or cause insulin resistance like full-length GH.

KEY DISTINCTION

Retains the fat-burning domain of GH with NONE of the anabolic, glucose, or IGF-1 side effects. No water retention, no insulin resistance, no musculoskeletal overgrowth.

SECONDARY BENEFIT

Chondroprotective — FDA granted Orphan Drug designation for osteoarthritis treatment. Stimulates cartilage and bone repair independent of fat loss effects.

      Why AOD-9604 over GH for fat loss: Full-length GH causes IGF-1 elevation, insulin resistance, and water retention at fat-burning doses. AOD-9604 isolates only the lipolytic domain — you get the fat loss effect with the safety profile of a peptide, not a hormone.
    

02 / RESEARCH HISTORY

Development Timeline

1990s

Researchers at Monash University (Australia) identify that the C-terminal fragment of hGH (residues 176–191) contains the fat-mobilizing domain. Full GH is too broad — this fragment isolates the mechanism.

2001

Metabolic Pharmaceuticals (Australia) begins clinical development. Phase I trials confirm safety and no effect on blood glucose or IGF-1 — validating the fragment approach.

2004–2007

Phase IIa/IIb trials in obese adults. Oral AOD-9604 (MK-0677) shows statistically significant fat reduction vs. placebo. SC formulation advances as more bioavailable route.

2014

FDA grants Orphan Drug designation for AOD-9604 in osteoarthritis — recognizing cartilage repair mechanism. Expands clinical profile beyond metabolic use.

2015–Present

Compounding pharmacies adopt AOD-9604 as part of metabolic/anti-obesity protocols. Widely stacked with GLP-1 agonists, peptides, and lifestyle interventions. Ongoing cartilage research continues.

03 / BENEFITS & MECHANISMS

Research-Supported Effects

01

Targeted Lipolysis — Visceral & Subcutaneous Fat

Binds β3-adrenergic receptors in adipose tissue to activate hormone-sensitive lipase (HSL). Preferentially breaks down stored triglycerides into free fatty acids — especially effective on visceral (deep belly) fat that resists diet and exercise.

02

Lipogenesis Inhibition — Stops Fat Storage

Simultaneously inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in fat synthesis. Dual action: breaks down existing fat AND prevents new fat from being stored from dietary intake.

03

Glucose & Insulin Neutral — No Metabolic Penalty

Unlike full-length hGH, AOD-9604 does NOT activate IGF-1 pathways or impair insulin sensitivity. Fasting glucose and HbA1c remain stable. Critical distinction for metabolic syndrome patients and diabetics.

04

Chondroprotection — Cartilage & Joint Repair

Independent mechanism via TGF-β stimulation. Promotes proteoglycan synthesis in articular cartilage, reduces joint space narrowing in animal osteoarthritis models. FDA Orphan Drug status validates this pathway. Particularly valuable stacked with BPC-157 or TB-500.

05

Clean Tolerability Profile

No water retention (no aldosterone pathway activation). No carpal tunnel risk. No gynecomastia risk. No suppression of endogenous GH. No impact on thyroid panel. Injection site reactions are mild and transient.

AOD-9604 ✓

Fat breakdown (lipolysis) ✓

Lipogenesis inhibition ✓

Cartilage repair ✓

Glucose neutral ✓

No IGF-1 elevation ✓

No water retention ✓

Full hGH — Fat Loss Dose

Fat breakdown ✓

IGF-1 elevation (anabolic) ⚠

Insulin resistance risk ⚠

Water retention ⚠

Carpal tunnel risk ⚠

Expensive + controlled ⚠

04 / RECONSTITUTION

Vial Preparation

🚨 CRITICAL — READ BEFORE RECONSTITUTING

Do NOT reconstitute AOD-9604 with bacteriostatic water alone. It will gel.

AOD-9604 is a 16-amino-acid peptide (sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). Six to eight of those residues are strongly hydrophobic — that's ~45% hydrophobic content, which is extremely high for a peptide this short. In pure water, the hydrophobic amino acids cluster together to escape water exposure, the peptide chains stack, and the solution forms a cloudy gel or precipitate.

✅ THE FIX — USE DILUTE ACETIC ACID

Reconstitute with 1 mL of 0.6–1% acetic acid solution + 2 mL bacteriostatic water (3 mL total for a 10mg vial).

Why acetic acid works (3 mechanisms):

Same-charge repulsion. The acid protonates the peptide's amino groups, making every AOD molecule positively charged. Like charges repel — molecules stay apart instead of clustering.
Weakened hydrophobic aggregation. Protonated surfaces are more polar, so the "oily patches" that drive clustering are neutralized.
Slowed disulfide cross-linking. AOD has two cysteine residues that form an internal S-S bond. In neutral aqueous solution those bonds can scramble and cross-link adjacent molecules. Acid dramatically slows that chemistry — the peptide stays monomeric.

🔧 TECHNIQUE (preserves the peptide)

Tilt the vial ~30 degrees.
Add liquid SLOWLY down the inside wall of the vial — never directly onto the powder. This prevents the peptide from being blasted or agitated.
Do NOT shake. Let the powder dissolve on its own. Swirl gently if needed, but patience wins.
If it still gels after dissolving, add another 0.5 mL of acetic acid solution.
Preload your syringes (or Apex pen cartridge) immediately. Every time you puncture the vial septum and pull a dose, you introduce air, pressure changes, and shaking — which can restart the aggregation cycle. Preload once, done.

🛒 WHERE TO BUY THE RIGHT ACETIC ACID

Do NOT use: household vinegar, apple cider vinegar, wood vinegar, glacial acetic acid, industrial / cleaning grade, or anything from a grocery store. Wrong concentration, not sterile, or contains contaminants.

What to buy: Sterile 0.6% acetic acid solution (also labeled "acetic acid water" or "AOD reconstitution solution"). Pre-diluted, pre-sterilized, 30 mL multi-dose vial with rubber septum. $15–25.

Label should say:

✓ Sterile
✓ 0.6% acetic acid
✓ Peptide / research grade
✓ 30 mL multi-dose vial

Recommended suppliers:

• Particle Peptides
• Amino Asylum
• Modern Amino
• Limitless Life Nootropics
• Simple Peptide
• SwissChems

Search term: "acetic acid water" or "AOD reconstitution solution"

STANDARD VIAL — 10mg (using acetic acid protocol)

10mg vial + 1.0 mL acetic acid (0.6–1%) + 2.0 mL BAC water = 3.0 mL total

Concentration: 33.3 mcg per unit (0.01 mL)

DOSE	MCG	UNITS (on syringe)	VOLUME
LOW	250mcg	7.5 units	0.075 mL
STANDARD	500mcg	15 units	0.15 mL
HIGH	750mcg	22.5 units	0.225 mL

🧊

RECONSTITUTED SHELF LIFE

21 days after mixing

Hydrophobic — aggregation risk grows with time. Use acetic acid protocol above; do not shake.

            Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze

            Preload syringes/cartridges to minimize vial disturbance

Storage: Lyophilized powder stable at room temp up to 6 months. Refrigerate (36–46°F / 2–8°C) for long-term storage. After reconstitution: refrigerate, use within 30 days. Protect from light. Do NOT freeze reconstituted vial.

05 / DOSING PROTOCOL

Dose Ranges

LEVEL	DOSE	FREQUENCY	USE CASE
LOW	250mcg / day	Daily	Sensitive individuals, first cycle, maintenance
STANDARD	500mcg / day	Daily	Active fat loss phase — most users start here
HIGH	750mcg / day	Daily	Accelerated protocol, upper research dose range

Oral vs. SC: Early Metabolic Pharmaceuticals trials used oral delivery — SC injection is significantly more bioavailable and is the standard for compounding pharmacy protocols. Oral AOD-9604 requires 10× higher doses to achieve equivalent plasma levels.

GLP-1 Stack Protocol: AOD-9604 + Semaglutide or Tirzepatide is a powerful combination. GLP-1s reduce appetite and caloric intake; AOD-9604 drives direct lipolysis. The two mechanisms are additive, not redundant. Standard: 500mcg AOD-9604 AM fasted + GLP-1 injection per individual protocol.

06 / TIMING & ADMINISTRATION

Injection Protocol

OPTIMAL WINDOW

Morning — Fasted State

WHY FASTED

Lipolysis is maximized when insulin is at baseline. Eating raises insulin → insulin blocks HSL (the fat-burning enzyme) → AOD-9604 effectiveness drops significantly. Inject 30–60 min before breakfast.

WAIT POST-INJECTION

Wait 30–60 minutes before eating. During this window, free fatty acids mobilized by AOD-9604 enter circulation and are available for oxidation (especially if light cardio is performed).

INJECTION SITE

Subcutaneous — abdomen (periumbilical region preferred for visceral fat targeting), outer thigh, or lateral deltoid. Rotate sites to prevent fibrosis.

PRE-WORKOUT OPTION

Some protocols use 30–45 min pre-fasted cardio. The mobilized fatty acids serve as fuel during exercise — a potent combination for body recomposition. Not required; morning fasted alone is effective.

CARTILAGE PROTOCOL

For joint/cartilage indication: timing less critical — AM or PM both effective. Consistent daily dosing is more important than precise timing window.

07 / BIOMARKER MONITORING

Recommended Lab Panel

METABOLIC — PRIMARY EFFECT MARKERS

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
Fasting Glucoseglucose (fasting)	CLINICAL70–99 mg/dL	OPTIMAL72–90 mg/dL	Should remain unchanged on AOD-9604 — divergence suggests stacking issue
Fasting Insulininsulin (fasting)	CLINICAL2–25 µIU/mL	OPTIMAL3–8 µIU/mL	Stability confirms no IR development; improvement expected over fat loss cycle
HbA1chemoglobin A1c	CLINICAL<5.7%	OPTIMAL<5.3%	Baseline; should not elevate. Fat loss may improve over course of cycle.
HOMA-IRcalculated index	CLINICAL<2.5	OPTIMAL<1.5	Insulin resistance index — calculate from glucose + insulin. Should improve.

SAFETY — GH AXIS CONFIRMATION

MARKER	CLINICAL RANGE	OPTIMAL TARGET	NOTES
IGF-1insulin-like growth factor 1	CLINICALAge-adjusted	OPTIMALStable	Should NOT elevate — confirms AOD-9604 is not activating GH receptor axis
Lipid Paneltotal cholesterol, LDL, HDL, TG	CLINICALStandard reference	OPTIMALTG <80 mg/dL	TG and LDL may improve as visceral fat mobilizes. Monitor for trajectory.
CRP (hs)high-sensitivity C-reactive protein	CLINICAL<3.0 mg/L	OPTIMAL<1.0 mg/L	Visceral fat reduction drives systemic inflammation down — track improvement

JOINT / CARTILAGE (if using for osteoarthritis)

MARKER	CLINICAL RANGE	NOTES
Cartilage Oligomeric Matrix ProteinCOMP	CLINICAL<10 µg/mL	Elevated in active cartilage breakdown — reduction indicates chondroprotection
MRI Joint Assessmentradiographic	CLINICAL—	Pre/post MRI at 12+ weeks for cartilage volume and joint space changes

08 / CYCLE PROTOCOL

Administration Schedule

CYCLE LENGTH

12–16 Weeks

FREQUENCY

Daily (7 days/week). Consistent daily dosing outperforms 5-on/2-off for fat loss — metabolic effect is cumulative.

OFF PERIOD

4–8 weeks off between cycles. No clinical evidence of tolerance, but cycling prevents receptor accommodation and allows metabolic assessment.

GOLD STACK: FAT LOSS

AOD-9604 500mcg AM + Semaglutide (per protocol) + MOTS-c 5mg AM. Triple metabolic attack: lipolysis + appetite + mitochondrial efficiency.

GOLD STACK: JOINT + FAT

AOD-9604 500mcg + BPC-157 500mcg + TB-500 2mg (2x/week). Fat mobilization with full joint and tissue repair support.

REQUIRES

Reconstitution with BAC water · Precise dosing with Apex V3 Pen · Refrigeration post-reconstitution

READY TO ADD THIS TO YOUR STACK?

Drop AOD-9604 into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Returns you here after.

⚠ Research reference only. AOD-9604 is not FDA-approved for human therapeutic use. Information sourced from published clinical and preclinical literature. Consult a qualified medical provider before use.